Century Therapeutics (IPSC) Long-Term Investments (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Long-Term Investments data on file, last reported at $82.2 million in Q1 2026.

• On a quarterly basis, Long-Term Investments rose 296.7% year-over-year to $82.2 million in Q1 2026; TTM through Mar 2026 was $82.2 million, a 296.7% increase from a year earlier, with the FY2024 full-year figure at $30.8 million, down 65.41% from the prior year.
• Long-Term Investments for Q1 2026 stood at $82.2 million, up from $2.7 million in the prior quarter.
• Over the last five years, Long-Term Investments for IPSC reached as high as $144.6 million in Q2 2023 and fell as low as $2.7 million in Q2 2025.
• Historically, Long-Term Investments has averaged $66.2 million across 5 years, with a median of $57.9 million in 2024.
• Across the five-year window, Long-Term Investments tumbled 96.33% in 2025 and surged 296.7% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $51.9 million in 2022, then surged by 71.82% to $89.1 million in 2023, then tumbled by 65.41% to $30.8 million in 2024, then tumbled by 91.27% to $2.7 million in 2025, then soared by 2954.61% to $82.2 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $82.2 million in Q1 2026, $2.7 million in Q2 2025, and $20.7 million in Q1 2025.